minimal Common Oncology Data Elements (mCODE) Implementation Guide
4.0.0 - STU4 United States of America flag

This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v4.0.0: STU4) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Patient Information
... 3 Disease Characterization
... 4 Assessment
... 5 Genomics
... 6 Treatments
... 7 Outcomes
... 8 Conformance Expectations
... 9 Identifying In-Scope Patients
... 10 Profile Conformance
... 11 USCDI+ Cancer Conformance
... 12 Terminology
... 13 Data Dictionary
... 14 Profiles
... 15 Extensions
... 16 Value Sets
... 17 Code Systems
... 18 Capability Statements
... 19 Artifacts Summary
.... 19.1 mCODE Data Receiver CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 19.2 mCODE Data Receiver CapabilityStatement: Get in-scope patients using reverse chaining
.... 19.3 mCODE Data Receiver: Get Bundle for a Patient
.... 19.4 mCODE Data Receiver: Get Conditions then Patients
.... 19.5 mCODE Data Receiver: Get Patients in Group
.... 19.6 mCODE Data Sender CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 19.7 mCODE Data Sender CapabilityStatement: Get in-scope patients using reverse chaining
.... 19.8 mCODE Data Sender: Get Bundle for a Patient
.... 19.9 mCODE Data Sender: Get Conditions then Patients
.... 19.10 mCODE Data Sender: Get Patients in Group
.... 19.11 Fetch mCODE Patient Bundle for a given Patient
.... 19.12 Search by code:in in Conditions
.... 19.13 Acute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set
.... 19.14 Benign Neoplasm of Brain and CNS Disorder Value Set
.... 19.15 Binet Stage Value Set
.... 19.16 Body Location and Laterality Qualifier Value Set
.... 19.17 Body Location Qualifier Value Set
.... 19.18 Brachytherapy High Dose Rate Electronic Technique Value Set
.... 19.19 Brachytherapy High Dose Rate Technique Value Set
.... 19.20 Brachytherapy Low Dose Rate Temporary Radiation Technique Value Set
.... 19.21 Brachytherapy Modality Value Set
.... 19.22 Brachytherapy Permanent Seeds Technique Value Set
.... 19.23 Brachytherapy Pulsed Dose Rate Technique Value Set
.... 19.24 Brachytherapy Radiopharmaceutical Technique Value Set
.... 19.25 Brachytherapy Technique Value Set
.... 19.26 Breslow Depth Stage Value Set
.... 19.27 Cancer Body Location Value Set
.... 19.28 Cancer Disease Status Evidence Type Value Set
.... 19.29 Cancer Disorder Value Set
.... 19.30 Cancer Stage Type Value Set
.... 19.31 Cancer Stage Value Set
.... 19.32 Cancer Staging Method Value Set
.... 19.33 Cancer Staging Prognostic Factors Types
.... 19.34 Cancer Staging Prognostic Factors Value
.... 19.35 Cancer-Related Surgical Procedure Value Set
.... 19.36 Carbon Ion Beam Technique Value Set
.... 19.37 Carcinoma In-Situ Disorder Value Set
.... 19.38 Clark Level Value Set
.... 19.39 Clinical or Pathologic Modifier
.... 19.40 Condition Status Trend Maximum Value Set
.... 19.41 Condition Status Trend Value Set
.... 19.42 Cytologic Evidence of Malignancy Value Set
.... 19.43 Deauville Scale Value Set
.... 19.44 Electron Beam Technique Value Set
.... 19.45 FAB Classification Value
.... 19.46 FIGO Stage Value Set
.... 19.47 FIGO Staging Method Value Set
.... 19.48 Gleason Grade Value Set
.... 19.49 Histologic Behavior and Type Value Set
.... 19.50 Histologic Grade Value Set
.... 19.51 Histologic Grading System Value Set
.... 19.52 Histology Morphology Behavior Value Set
.... 19.53 History of Metastatic Malignant Neoplasm Value Set
.... 19.54 Human Specimen Type Value Set
.... 19.55 International Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set
.... 19.56 International Neuroblastoma Staging System (INSS) for Neuroblastoma Stage Value Set
.... 19.57 International Retinoblastoma Stage Value
.... 19.58 International Staging System (ISS) for Myeloma Stage Value Set
.... 19.59 Lansky Play Performance Status VS
.... 19.60 Laterality Qualifier Value Set
.... 19.61 Lymphoma Stage Bulky Modifier Value Set
.... 19.62 Lymphoma Stage Value Modifier Value Set
.... 19.63 Lymphoma Stage Value Set
.... 19.64 Lymphoma Staging System Value Set
.... 19.65 Melanoma In-Situ Disorder Value Set
.... 19.66 Neutron Beam Technique Value Set
.... 19.67 Normalization Basis Value Set
.... 19.68 Photon Beam Technique Value Set
.... 19.69 PRETEXT Stage Value
.... 19.70 Primary Cancer Disorder Value Set
.... 19.71 Primary Malignant Neoplasm Disorder Value Set
.... 19.72 Procedure Intent Value Set
.... 19.73 Proton Beam Technique Value Set
.... 19.74 Radiotherapy Modality Value Set
.... 19.75 Radiotherapy Technique Value Set
.... 19.76 Radiotherapy Treatment Location Qualifier Value Set
.... 19.77 Radiotherapy Treatment Location Value Set
.... 19.78 Radiotherapy Volume Type Value Set
.... 19.79 Rai Stage Value Set
.... 19.80 Rai Staging System Value Set
.... 19.81 Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set
.... 19.82 Rhabdomyosarcoma Assessment Value Set
.... 19.83 Rhabdomyosarcoma Clinical Group Value
.... 19.84 Risk Assessment Type Value Set
.... 19.85 Risk Assessment Value Set
.... 19.86 Secondary Cancer Disorder Value Set
.... 19.87 Specific Diagnosis of Cancer Value Set
.... 19.88 Teleradiotherapy Modality Value Set
.... 19.89 Teleradiotherapy Technique Value Set
.... 19.90 TG263 ValueSet
.... 19.91 TNM Distant Metastases Category Value Set
.... 19.92 TNM Distant Metastases Maximum Value Set
.... 19.93 TNM Distant Metastases Staging Type Maximum Value Set
.... 19.94 TNM Distant Metastases Staging Type Value Set
.... 19.95 TNM Primary Tumor Category Value Set
.... 19.96 TNM Primary Tumor Maximum Value Set
.... 19.97 TNM Primary Tumor Staging Type Maximum Value Set
.... 19.98 TNM Primary Tumor Staging Type Value Set
.... 19.99 TNM Regional Nodes Category Value Set
.... 19.100 TNM Regional Nodes Maximum Value Set
.... 19.101 TNM Regional Nodes Staging Type Maximum Value Set
.... 19.102 TNM Regional Nodes Staging Type Value Set
.... 19.103 TNM Stage Group Maximum Value Set
.... 19.104 TNM Stage Group Staging Type Maximum Value Set
.... 19.105 TNM Stage Group Staging Type Value Set
.... 19.106 TNM Stage Group Value Set
.... 19.107 TNM Staging Method Value Set
.... 19.108 Treatment Termination Reason Value Set
.... 19.109 Tumor Marker Test Value Set
.... 19.110 Tumor Morphology Code Max Value Set
.... 19.111 Tumor Morphology Code Value Set
.... 19.112 Tumor Size Method Value Set
.... 19.113 Tumor Size Units Value Set
.... 19.114 Wilms Tumor Body Site Value Set
.... 19.115 Wilms Tumor Stage Value Set
.... 19.116 TG263 CodeSystem
.... 19.117 TG263 Concept Map
.... 19.118 all-risk-assessment-high
.... 19.119 all-risk-assessment-standard-brian-l
.... 19.120 binet-stage-group-B
.... 19.121 body-surface-area-brian-l
.... 19.122 body-surface-area-example
.... 19.123 bodyheight-jenny-m-2018-03-06
.... 19.124 bodyweight-jenny-m-2018-03-16
.... 19.125 bodyweight-jenny-m-2018-04-22
.... 19.126 bone-marrow-aspirate-result-brian-l
.... 19.127 bone-marrow-biopsy-result-brian-l
.... 19.128 cancer-disease-status-improved
.... 19.129 cancer-disease-status-improved-brian-l
.... 19.130 cancer-disease-status-jenny-m
.... 19.131 cancer-patient-adam-everyman
.... 19.132 cancer-patient-brian-l
.... 19.133 cancer-patient-eve-anyperson
.... 19.134 cancer-patient-jenny-m
.... 19.135 cancer-patient-john-anyperson
.... 19.136 cancer-patient-lucy-child
.... 19.137 cancer-related-comorbidities-jenny-m
.... 19.138 cancer-related-comorbidities-john-anyperson
.... 19.139 cancer-related-medication-admin-cyclophosphamide-brian-l
.... 19.140 cancer-related-medication-admin-cyclophosphamide-jenny-m
.... 19.141 cancer-related-medication-admin-doxorubicin-jenny-m
.... 19.142 cancer-related-medication-admin-idarubicin-brian-l
.... 19.143 cancer-related-medication-admin-paclitaxel-jenny-m
.... 19.144 cancer-related-medication-admin-prednisone-brian-l
.... 19.145 cancer-related-medication-admin-vincristine-brian-l
.... 19.146 cancer-related-medication-request-anastrozole-jenny-m
.... 19.147 cancer-related-medication-request-cisplatin
.... 19.148 cancer-related-medication-request-cisplatin-stopped
.... 19.149 cancer-related-medication-request-cyclophosphamide-brian-l
.... 19.150 cancer-related-medication-request-cyclophosphamide-jenny-m
.... 19.151 cancer-related-medication-request-doxorubicin-jenny-m
.... 19.152 cancer-related-medication-request-gefitinib
.... 19.153 cancer-related-medication-request-idarubicin-brian-l
.... 19.154 cancer-related-medication-request-paclitaxel-jenny-m
.... 19.155 cancer-related-medication-request-prednisone-brian-l
.... 19.156 cancer-related-medication-request-vincristine-brian-l
.... 19.157 cancer-related-surgical-procedure-jenny-m
.... 19.158 cancer-related-surgical-procedure-lobectomy
.... 19.159 deauville-scale-five
.... 19.160 ecog-performance-status-fully-active
.... 19.161 ecog-performance-status-jenny-m
.... 19.162 family-member-history-aunt-jenny-m
.... 19.163 family-member-history-grandmother-brian-l
.... 19.164 family-member-history-sister-jenny-m
.... 19.165 family-member-history-uncle-jenny-m
.... 19.166 figo-stage-IIIA
.... 19.167 genomic-region-studied-jenny-m
.... 19.168 genomic-region-studied-stk11
.... 19.169 genomic-variant-fusion
.... 19.170 genomic-variant-germline-deletion
.... 19.171 genomic-variant-jenny-m
.... 19.172 genomic-variant-somatic-single-nucleotide
.... 19.173 genomics-report-jenny-m
.... 19.174 genomics-report-john-anyperson
.... 19.175 gleason-grade-group-4
.... 19.176 gx-cancer-patient-adam-anyperson
.... 19.177 gx-genomic-bundle-adam-anyperson
.... 19.178 gx-genomic-diagnostic-implication-bap1
.... 19.179 gx-genomic-diagnostic-implication-pof1b
.... 19.180 gx-genomic-diagnostic-implication-polrmt
.... 19.181 gx-genomic-msi
.... 19.182 gx-genomic-specimen-tumornormal-normal
.... 19.183 gx-genomic-specimen-tumornormal-tumor
.... 19.184 gx-genomic-therapeutic-implication-alectinib
.... 19.185 gx-genomic-therapeutic-implication-brigatinib
.... 19.186 gx-genomic-therapeutic-implication-ceritinib
.... 19.187 gx-genomic-therapeutic-implication-crizotinib
.... 19.188 gx-genomic-therapeutic-implication-lorlatinib
.... 19.189 gx-genomic-tmb
.... 19.190 gx-genomic-variant-fusion-ETV6-RUNX1-brian-l
.... 19.191 gx-genomic-variant-fusion-met-alk
.... 19.192 gx-genomic-variant-pertinent-negative-nras-kit-braf
.... 19.193 gx-genomic-variant-somatic-bap1-indel
.... 19.194 gx-genomic-variant-somatic-cdkn2a-cnv
.... 19.195 gx-genomic-variant-somatic-cdkn2b-cnv
.... 19.196 gx-genomic-variant-somatic-kdm5d
.... 19.197 gx-genomic-variant-somatic-mtap
.... 19.198 gx-genomic-variant-somatic-mycn
.... 19.199 gx-genomic-variant-somatic-pof1b
.... 19.200 gx-genomic-variant-somatic-polrmt
.... 19.201 gx-genomics-report-adam-anyperson
.... 19.202 gx-order-tumornormal-gensop-inc
.... 19.203 gx-practitioner-test-pathologist
.... 19.204 gx-us-core-organization-gensop-inc
.... 19.205 hematocrit-brian-l
.... 19.206 hemoglobin-brian-l
.... 19.207 histologic-behavior-and-type-non-small-cell
.... 19.208 histologic-grade-intermediate
.... 19.209 history-of-cancer-metastatic-to-liver
.... 19.210 hodgkins-lymphoma-stage-IIIe
.... 19.211 human-specimen-left-breast-jenny-m
.... 19.212 human-specimen-lung
.... 19.213 immunophenotype-brian-l
.... 19.214 jenny-m-chest-wall-lymph-nodes-treatment-volume
.... 19.215 jenny-m-chest-wall-treatment-volume
.... 19.216 john-anyperson-chf
.... 19.217 john-anyperson-hd
.... 19.218 john-anyperson-treatment-volume
.... 19.219 karnofsky-performance-status-normal-activity
.... 19.220 lab-result-observation-hemoglobin
.... 19.221 lansky-performance-status-brian-l
.... 19.222 lansky-play-performance-status-twenty
.... 19.223 mCODE Patient Group Example
.... 19.224 mcode-patient-bundle-jenny-m
.... 19.225 melanoma-breslow-depth-stage
.... 19.226 melanoma-clark-level-4
.... 19.227 multiple-myeloma-iss-stage-II
.... 19.228 multiple-myeloma-riss-stage-II
.... 19.229 neuroblastoma-inrgss-stage-MS
.... 19.230 neuroblastoma-inss-stage-III
.... 19.231 no-history-of-metastatic-cancer
.... 19.232 observation-smoking-pack-years-jenny-m
.... 19.233 primary-cancer-condition-breast
.... 19.234 primary-cancer-condition-brian-l
.... 19.235 primary-cancer-condition-cll
.... 19.236 primary-cancer-condition-jenny-m
.... 19.237 primary-cancer-condition-nonspecific
.... 19.238 primary-cancer-condition-nsclc
.... 19.239 radiotherapy-treatment-summary-chest-wall-jenny-m
.... 19.240 radiotherapy-treatment-summary-other-with-text
.... 19.241 rai-stage-II
.... 19.242 rhabdomyosarcoma-clinical-group-stage-IA
.... 19.243 rhabdomyosarcoma-risk-assessment-low
.... 19.244 secondary-cancer-condition-brain-mets
.... 19.245 tnm-clinical-distant-metastases-category-cM0
.... 19.246 tnm-clinical-distant-metastases-category-jenny-m
.... 19.247 tnm-clinical-primary-tumor-category-cT3
.... 19.248 tnm-clinical-primary-tumor-category-jenny-m
.... 19.249 tnm-clinical-regional-nodes-category-cN3
.... 19.250 tnm-clinical-regional-nodes-category-jenny-m
.... 19.251 tnm-clinical-stage-group-3c
.... 19.252 tnm-clinical-stage-group-jenny-m
.... 19.253 tnm-pathologic-distant-metastases-category-jenny-m
.... 19.254 tnm-pathologic-primary-tumor-category-jenny-m
.... 19.255 tnm-pathologic-regional-nodes-category-jenny-m
.... 19.256 tnm-pathologic-stage-group-jenny-m
.... 19.257 tumor-lobular-carcinoma-left-breast
.... 19.258 tumor-marker-test-egf
.... 19.259 tumor-marker-test-er-jenny-m
.... 19.260 tumor-marker-test-her2-jenny-m
.... 19.261 tumor-marker-test-oncotype-dx-jenny-m
.... 19.262 tumor-marker-test-pr-jenny-m
.... 19.263 tumor-morphology-report-non-small-cell-intermediate-grade
.... 19.264 tumor-size-jenny-m
.... 19.265 tumor-size-pathology
.... 19.266 tumor-specimen-left-breast-jenny-m
.... 19.267 tumor-specimen-lobular-carcinoma-left-breast
.... 19.268 us-core-condition-anxiety-jenny-m
.... 19.269 us-core-condition-atrial-septal-defect-brian-l
.... 19.270 us-core-condition-depression-jenny-m
.... 19.271 us-core-condition-hypertension-jenny-m
.... 19.272 us-core-diagnosticreport-cbc-brian-l
.... 19.273 us-core-diagnosticreport-lab-jenny-m
.... 19.274 us-core-lumbar-puncture-result-brian-l
.... 19.275 us-core-observation-lab-neutrophils-jenny-m
.... 19.276 us-core-observation-lab-sentinel-nodes-jenny-m
.... 19.277 us-core-observation-lab-tumor-dcis-jenny-m
.... 19.278 us-core-observation-lab-tumor-grade-jenny-m
.... 19.279 us-core-observation-lab-tumor-invasion-jenny-m
.... 19.280 us-core-observation-lab-tumor-margins-jenny-m
.... 19.281 us-core-organization-bedrock-medicine
.... 19.282 us-core-organization-physician-services-inc
.... 19.283 us-core-practitioner-jane-radiotech
.... 19.284 us-core-practitioner-kyle-anydoc
.... 19.285 us-core-practitioner-mary-obgyn
.... 19.286 us-core-practitioner-nancy-oncology-nurse
.... 19.287 us-core-practitioner-owen-oncologist
.... 19.288 us-core-practitioner-peter-pathologist
.... 19.289 us-core-procedure-biopsy-jenny-m
.... 19.290 us-core-procedure-bone-marrow-aspiration-brian-l
.... 19.291 us-core-procedure-bone-marrow-biopsy-brian-l
.... 19.292 us-core-procedure-lumbar-puncture-brian-l
.... 19.293 us-core-procedure-mammogram-jenny-m
.... 19.294 us-core-smokingstatus-jenny-m
.... 19.295 white-blood-cell-brian-l
.... 19.296 wilms-tumor-stage-III
.... 19.297 ALL Risk Assessment Profile
.... 19.298 Body Location Qualifier Extension
.... 19.299 Body Structure Identifier Profile
.... 19.300 Body Surface Area
.... 19.301 Cancer Disease Status Evidence Type Extension
.... 19.302 Cancer Disease Status Profile
.... 19.303 Cancer Patient Profile
.... 19.304 Cancer Risk Assessment Profile
.... 19.305 Cancer Stage Profile
.... 19.306 Cancer-Related Medication Administration Profile
.... 19.307 Cancer-Related Medication Request Profile
.... 19.308 Cancer-Related Surgical Procedure Profile
.... 19.309 Comorbidities Profile
.... 19.310 Deauville Scale Profile
.... 19.311 ECOG Performance Status Profile
.... 19.312 Genomic Region Studied Profile
.... 19.313 Genomic Variant Profile
.... 19.314 Genomics Report Profile
.... 19.315 Histologic Behavior and Type
.... 19.316 Histologic Grade
.... 19.317 Histology-Morphology-Behavior Extension
.... 19.318 History of Metastatic Cancer
.... 19.319 Human Specimen Profile
.... 19.320 Karnofsky Performance Status Profile
.... 19.321 Lansky Play Performance Status Profile
.... 19.322 Laterality Qualifier Extension
.... 19.323 Lymphoma Stage Profile
.... 19.324 mCODE Patient Bundle Profile
.... 19.325 mCODE Patient Group Profile
.... 19.326 Normalization Basis Extension
.... 19.327 Parent for T, N, and M Categories.
.... 19.328 Primary Cancer Condition Profile
.... 19.329 Procedure Intent Extension
.... 19.330 Radiotherapy Course Summary Profile
.... 19.331 Radiotherapy Dose Delivered To Volume Extension
.... 19.332 Radiotherapy Modality And Technique Extension
.... 19.333 Radiotherapy Modality Extension
.... 19.334 Radiotherapy Number of Sessions Extension
.... 19.335 Radiotherapy Technique Extension
.... 19.336 Radiotherapy Volume Profile
.... 19.337 Related Condition Absent Extension
.... 19.338 Related Condition Extension
.... 19.339 Rhabdomyocaroma Risk Assessment Profile
.... 19.340 Secondary Cancer Condition Profile
.... 19.341 TNM Distant Metastases Category Profile
.... 19.342 TNM Primary Tumor Category Profile
.... 19.343 TNM Regional Nodes Category Profile
.... 19.344 TNM Stage Group Profile
.... 19.345 Treatment Termination Reason Extension (deprecated)
.... 19.346 Tumor Marker Test Profile
.... 19.347 Tumor Morphology Report
.... 19.348 Tumor Profile
.... 19.349 Tumor Size Profile
... 20 Basic Examples
... 21 Genomics Examples
... 22 Extended Example
... 23 Extended Pediatric Example
... 24 Release Notes
... 25 Glossary
... 26 Download Specification
... 27 mCODE Implementation Guide Resource